Penn Vet Researchers Invent Skin‑targeted Dual mRNA Vaccine Platform to Deliver Long‑lasting Protection Against Cutaneous Leishmaniasis

Phillip Scott, PhD, Professor of Microbiology and Immunology, Department of Pathobiology at Penn Vet, in collaboration with Drew Weismann, MD, PhD, the Roberts Family Professor in Vaccine Research at Penn Medicine and Mohamad Gabriel Alameh, PhD, Assistant Professor of Pathology and Laboratory Medicine at Penn Medicine, developed a vaccine against Cutaneous Leishmaniasis, a disease that causes painful and disfiguring skin lesions.

This experimental vaccine uses mRNA technology to train immune cells to recognize the parasite that causes cutaneous. By creating long-lasting immune protection in the skin, this technology has the potential to help prevent infections and potentially protect against other skin-related infectious diseases. Learn more here.

PCI is actively seeking partners and investors for further development of this promising technology. For more information, please contact Neetu Singh Amin, PhD, Associate Director of Licensing for Penn Vet. 

Skip to content